Trials / Completed
CompletedNCT03002428
A Comparison of PF708 and Forteo in Osteoporosis Patients
A Randomized Study Comparing the Effects of PF708 and Forteo in Patients With Osteoporosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 181 (actual)
- Sponsor
- Pfenex, Inc · Industry
- Sex
- All
- Age
- 30 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effects of two teriparatide products, PF708 and Forteo, in patients with osteoporosis.
Detailed description
This is a randomized, multi-center study conducted in the United States. Men and women with osteoporosis will be enrolled in a parallel-group, open-label study design to compare the effects of PF708 and Forteo after 24 weeks of treatment. Half of the subjects will be randomized to receive PF708, and the other half will be randomized to receive Forteo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teriparatide (PF708) | Subcutaneous injection |
| DRUG | Teriparatide (Forteo) | Subcutaneous injection |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
- First posted
- 2016-12-23
- Last updated
- 2018-05-23
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03002428. Inclusion in this directory is not an endorsement.